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Background and Objective: Iron deficiency is a frequent complication of chronic kidney disease 
(CKD) that is associated with a decrease in the quality of life of patients and an increase in the 
risk of suffering other clinical complications. Iron therapy represents one of the fundamentals 
of patients with CKD. Sucrosomial® oral iron allows that Fisiogen Ferro Forte® can be used in 
all those patients who turn out to be intolerant to treatment by oral route or who present a 
malabsorption of conventional oral iron preparations. The main objective is to assess the 
economic impact of the oral iron Fisiogen Ferro Forte® for the management of iron deficiency 
in CKD patients in Spain. 
Methods: A 4-year budget impact model was developed for the period 2017-2020 for CKD 
patients with iron deficiency candidates for intravenous iron due to a lack of response to oral 
iron from the Spanish Healthcare System perspective. Three subgroups of CKD patients were 
included in the analysis: pre-dialysis, peritoneal dialysis and post-transplant. Ferinject®, 
Venofer® and Feriv® were the intravenous iron formulations considered as appropriate 
comparators to be used in the model. National data on CKD prevalence for the three 
subgroups of patients were obtained from the literature. Input data on drug utilization and 
outpatient hospitalizations associated with iron administration were obtained by consulting 
nephrologists. Nephrology experts were also asked about resources of medical visits and 
monitoring tests. Based on the unit costs for each iron therapy and resources used, the total 
treatment cost per patient associated with each product was obtained to estimate the global 
budget impact of increasing the use of Fisiogen Ferro Forte®.  
Results: The average annual budget savings with an increase of Fisiogen Ferro Forte® and a 
decrease of intravenous iron was estimated at €398,685, €180,937 and €195,842 over the next 
four years for pre-dialysis, peritoneal dialysis and post-transplant groups respectively. 
Conclusions: The increase in the use of Fisiogen Ferro Forte® leads to overall savings of 
€775,464 in the budget for the Spanish NHS over the next 4 years.  
 
Key points: The increase in the use of Fisiogen Ferro Forte® leads to overall savings in the 




Chronic kidney disease (CKD) is an emerging health problem throughout the world. In Spain, 
according to the results of the EPIRCE study, designed to know the prevalence of CKD and 
promoted by the Spanish Society of Nephrology with the support of the Ministry of Health and 
Consumption, it was estimated that approximately 10% of the adult population suffered from 
some degree of CKD [1]. Factors such as the aging of the population, the high prevalence of 
cardiovascular risk factors in the population (such as diabetes, hypertension or dyslipidemia) 
or early diagnosis, would be the reason of this increase in the CKD incidence [1].  
Iron deficiency is a frequent complication of CKD that is associated with a decrease in 
hemoglobin levels that is related also with a decrease in the quality of life of patients and an 
increase in the risk of suffering other clinical complications, including a significant increase in 
cardiovascular risk [2]. The main cause of anemia in CKD is the inadequate production of 
endogenous erythropoietin, a hormone that acts on the differentiation and maturation of the 
precursors of the red blood cells. In addition, iron deficiency already appears in early stages of 
the disease. In more advanced phases and in patients on dialysis, around 90% of patients have 
an iron deficiency [3].  
In the therapeutic approach of iron deficiency associated with renal failure, iron therapy 
represents one of the main treatment modalities of patients with CKD. In patients undergoing 
hemodialysis, the intravenous route is of choice but according to the latest KDIGO guidelines 
[4], published in 2014, there is not enough scientific evidence to affirm that the intravenous 
route is superior to oral administration in patients with CKD, not subject to hemodialysis. 
Treatment with conventional iron salts, administered orally, can often not effectively resolve 
the medical situation. Patients with CKD used to present a generalized inflammatory state 
making iron salts absorption very difficult. The absorption difficulty involves numerous 
problems of tolerability causing problems in achieving a good therapeutic compliance. 
Despite this, in dialysis patients, oral iron can be especially the appropriate route to the need 
to preserve the venous tree by the time they need to enter into a hemodialysis process.  
The development of new technologies, such as the coverage of iron in sucrosomes, to avoid 
the appearance of adverse effects without compromising the already low bioavailability of iron 
is a very topical issue. This new technology reduces the possible interactions of iron 
compounds with other components of the diet that can decrease even more their 
bioavailability, such as tannins, polyphenols and phytates. 
It also reduces the irritation often caused by iron compounds in the gastric mucosa and it 
allows its absorption bypassing the hepcidin-dependent pathways involved in conventional 
iron absorption, being M cells from reticuloendothelial system a key pathway contributing to 
its absorption also in an inflammatory context [5,6].  
Sucrosomial® oral iron allows that Fisiogen Ferro Forte® can be used in all those patients who 
are intolerant to treatment by oral route or who present a malabsorption of conventional oral 
iron preparations [5,6]. 
The distinguishing features of Fisiogen Ferro Forte® make it possible to use it in all those 
patients, who are intolerant to oral treatment or who present a malabsorption of conventional 
oral iron preparations whose bioavailability is excessively limited, thus guaranteeing 
therapeutic adherence to treatment with oral iron and the consequent recovery of blood 
parameters [7-11].  
Different pharmacoeconomic analyses [12,13] have been published, where the drugs assessed 
were all intravenous (i.v.) iron solutions. These studies have shown that ferric carboxymaltose 
(Ferinject®) provide savings from the perspective of the national health service (NHS) because 
of the shorter duration of intravenous administration compared to the other iron solutions 
assessed in the studies.  
In the current study, we evaluated the expected economic impact from the increase in the 
market share of Fisiogen Ferro Forte® for the management of iron deficiency in patients with 
different CKD stages from the perspective of the Spanish NHS by using a budget impact model.  
 
2. METHODS 
Model Development and Structure  
The budget impact model (BIM) was developed in Microsoft Excel from the perspective of the 
Spanish NHS. We assessed differences among three subgroups of patients who can benefit 
from the use of Fisiogen Ferro Forte®. Each subgroup represents a specific stage of CKD: pre-
dialysis, peritoneal dialysis and post-transplant. Ferinject®, Venofer® and Feriv® were the i.v. 
iron formulations considered as appropriate comparators to be used in the model, given that 
constitute the iron deficiency maintenance treatment options in patients who do not respond 
to oral iron treatment due to problems of absorption or intolerance. The model analysed drug 
utilization for each subgroup of patients receiving iron supplementation based on their 
maintenance dose and number of doses required per year to treat the iron deficiency and its 
consequences, as well as the outpatient hospitalizations (Day hospital stay of a few hours, 
sometimes minutes) associated with the administration of i.v. iron formulations. Other medical 
resources use was based on the mean number of events for medical visits and iron deficiency 
monitoring tests required per year. The differences in product and medical costs associated 
with each treatment option, as well as the global budget impact of the forecast uptake of 
Fisiogen Ferro Forte®, were estimated from 2017 to 2020. 
The model included prevalent CKD patients estimated for each analysed subgroup, who 
control iron deficiency with an iron maintenance treatment but cannot receive oral iron. A 
panel of experts from different Spanish hospitals provided information on drug utilization and 
medical resources associated with iron maintenance therapy (outpatient hospitalizations, 
medical visits and monitoring tests). Annual costs of drugs and medical resources associated 
with iron maintenance therapy were reported in Euros (EUR 2017).   
The model generated estimates for the annual cost per patient including drug and medical 
costs to calculate the global budget impact based on market shares and prevalence data.  
Model Input Variables 
A panel of experts were consulted about some specific data that cannot be found in the 
literature or in the guidelines. In order to obtain the data requested, the experts have filled a 
questionnaire in which they were asked for data about epidemiology, treatments, dosage and 
healthcare resources use for the three subgroups of patients considered in this study.   
Target population 
To estimate the target population comprising CKD patients with iron deficiency candidates for 
i.v. iron supplementation the following algorithm was applied as shown in Figure 1. A literature 
review was performed to identify the prevalence of CKD for each stage of disease: 0.03% 
among the Spanish adult population (pre-dialysis) [14] and 0.11% among the Spanish 
population (stage 5D) [15]. Within the last group, a 5.5% correspond to patients in peritoneal 
dialysis and a 51.5% to post-transplant patients. The estimate for each stage of CKD has been 
extrapolated to the Spanish adult population obtained from the population projections 
conducted by the National Institute of Statistics (INE) [16]. The number of adult patients in 
Spain who present iron deficiency was estimated respectively for each stage of disease based 
on a panel of experts in nephrology:  65% (pre-dialysis), 82.5% (peritoneal dialysis) and 50% 
(post-transplant). The percentage of adult patients who are candidates for i.v. iron 
supplementation was estimated respectively for each stage of disease based on a panel of 
experts in nephrology: 52.5% (pre-dialysis), 85% (peritoneal dialysis) and 10% (post-
transplant). 
It must be taken into account that, due to the lack of data regarding iron deficiency prevalence 
in CKD patients, anemia data have been considered. In addition, it should be taken into 
account that using the anemia data provides more restrictive results than using the iron 
deficiency data.  
Drug treatments and costs 
The iron maintenance doses associated with each treatment for the different subgroups of 
patients receiving iron supplementation and the number of doses required per drug per year 
were estimated based on data from clinical practice by a panel of two clinical experts in 
nephrology from different Spanish hospitals (Table 1). Based on the average number of doses 
per year for the i.v. iron formulations, the number of 3-month treatments per year for Fisiogen 
Ferro Forte® and the unit costs per dose in EUR, the annual pharmacological treatment cost for 
each iron product was calculated. Prices were obtained from a Spanish Database of 
Pharmacists [17] and were expressed in EURO 2017. 
Furthermore, we assumed that the increase of Fisiogen Ferro Forte® was offset by a decrease 
in the market share of the i.v. iron formulations.    
Medical Resource Utilization and Costs 
Healthcare resources utilisation and costs included in the model were outpatient 
hospitalizations associated with the i.v. iron formulations administration, medical visits and 
monitoring tests (Table 2). The medical resources associated with each drug were based on the 
consultation of an expert panel of nephrologists and unit costs were obtained from the 
regional tariff lists of Madrid [18] and Valencia [19] (Table 2). The costs for the primary care 
visit and the Day hospital stay were obtained from the tariffs list of Madrid and the costs for 
the specialist physician, the nurse and the laboratory tests were obtained from the tariffs list 
of Valencia.  
 
Budgetary impact analysis 
Our model has estimated annual drug and healthcare resource cost per patient and allowed us 
to calculate for each treatment option, the annual cost per patient in EUR 2017. Based on the 
annual average cost per patient, the target population and the actual market shares for the 
products included in this study, the budget impact of the maintenance iron therapy for the 
treatment of iron deficiency was obtained for 2017-2020. The actual market shares for 2017 
were based on data of IMS [20] on the actual distribution of iron products (Table 3). This 
current scenario was compared with an alternative scenario in which the economic impact was 
conducted considering an increase in the use of Fisiogen Ferro Forte®. This increase has been 
calculated following the growing of Fisiogen Ferro Forte® during the last years.  The BIM was 
based on the difference found between the alternative scenario and the current scenario. 
Deterministic sensitivity analysis 
A one-way sensitivity analysis has been conducted in order to assess the robustness of the 
model. In order to include all the possible scenarios, the main variables were included in this 
sensitivity analysis.  The base case parameter for each variable was varied from the default 
value within reasonable lower and upper limits by using data from expert consultation and 
variations of 50% were applied to parameters for which no ranges were identified in the 
published literature.   
  
3. RESULTS 
We present the results of the BIM separately for the different stages of disease: pre-dialysis, 
peritoneal dialysis and post-transplant. The results show the economic impact of the 
treatment of iron deficiency and low haemoglobin in the different CKD stages from 2017 to 
2020 for the total of Spain.  
 
Pre-dialysis 
In our model based on the prevalence of iron deficiency and low haemoglobin in patients with 
CKD in pre-dialysis stage, and i.v. iron use it would be expected that 3,700 patients in 2017 
diagnosed with iron deficiency and CKD receive treatment with i.v. iron. Based on population 
trends this number decreases slightly to 3,683 patients in 2020 (Table 4). 
In the base case analysis in the current scenario before the increase of the market share of 
Fisiogen Ferro Forte® the total economic impact for the treatment with i.v. iron for patients 
with iron deficiency and CKD in pre-dialysis stage was estimated at €4.31 million, €4.23 million, 
€4.15 million and €4.06 million for the years 2017, 2018, 2019 and 2020, respectively (Table 5).  
When the market share of Fisiogen Ferro Forte® was increased to 3%, 5%, 8% and 10% in 2017, 
2018, 2019 and 2020 respectively, matched with a reduction in the share of the i.v. iron, the 
total economic impact was estimated at €4.27 million, €4.16 million, €4.03 million and €3.92 
million in 2017, 2018, 2019 and 2020 respectively (Table 6). Overall, the total budget savings 
with the modified market shares with an annual increase of Fisiogen Ferro Forte® and 
decrease of i.v. iron were expected to be €376,041 over the next four years (Table 5).  
At patient level, the average annual cost per patient in the current scenario decreases from 
2017 to 2020 from €1,166 to €1,104 and further, the cost per patient would be less with 
€1,064 in the alternative scenario. The average cost per patient over the period 2017-2020 
with the increase in the market share of Fisiogen Ferro Forte® was €25 lower with €1,135 
annual costs per patient than in the current scenario with €1,109 (Table 5). 
Peritoneal dialysis 
In our model based on the prevalence of iron deficiency in patients with CKD stage 5D 
(peritoneal dialysis), and i.v. iron use it would be expected that 1,989 patients in 2017 
diagnosed with iron deficiency and low haemoglobin and CKD receive treatment with i.v. iron. 
Based on population trends this number decreases slightly to 1,980 patients in 2020 (Table 5). 
In the base case analysis in the current scenario before the increase of the market share of 
Fisiogen Ferro Forte® the total economic impact for the treatment with i.v. iron for patients 
with iron deficiency and CKD stage 5D (peritoneal dialysis) was estimated at €2.22 million, 
€2.16 million, €2.10 million and €2.04 million for the years 2017, 2018, 2019 and 2020 
respectively (Table 6). 
When the market share of Fisiogen Ferro Forte® was increased to 3%, 5%, 8% and 10% in 2017, 
2018, 2019 and 2020 respectively, matched with a reduction in the share of the i.v. iron, the 
total economic impact was estimated at €2.20 million, €2.13 million, €2.06 million and €1.99 
million in 2017, 2018, 2019 and 2020 respectively (Table 6). Overall, the total budget savings 
with the modified market shares with an annual increase of Fisiogen Ferro Forte® and 
decrease of i.v. iron was expected to be €122,490over the next four years (Table 5).  
At patient level, the average annual cost per patient in the current scenario decreases from 
2017 to 2020 from €1,114 to €1,030 and further, the cost per patient would be less with 
€1,006 in the alternative scenario. The average cost per patient over the period 2017-2020 
with the increase in the market share of Fisiogen Ferro Forte® was €15 lower with €1,072 
annual costs per patient than in the current scenario with €1,056 (Table 5). 
Post-transplant 
In our model based on the prevalence of iron deficiency in patients with stage 5D CKD with 
functioning kidney transplant, and i.v. iron use it would be expected that 1,328 patients in 
2017 diagnosed with iron deficiency and CKD receive treatment with i.v. iron. Based on 
population trends this number decreases slightly to 1,322 patients in 2020 (Table 5).  
In the base case analysis in the current scenario before the increase of the market share of 
Fisiogen Ferro Forte® the total economic impact for the treatment with i.v. iron for patients 
with iron deficiency and stage 5D CKD with functioning kidney transplant was estimated at 
€1.82 million, €1.79 million, €1.77 million and €1.75 million for the years 2017, 2018, 2019 and 
2020 respectively (Table 5). 
When the market share of Fisiogen Ferro Forte® was increased to 3%, 5%, 8% and 10% in 2017, 
2018, 2019 and 2020 respectively, matched with a reduction in the share of the i.v. iron, the 
total economic impact was estimated at €1.79 million, €1.76 million, €1.72 million and €1.66 
million in 2017, 2018, 2019 and 2020 respectively (Table 5). Overall, the total budget savings 
with the modified market shares with an annual increase of Fisiogen Ferro Forte® and 
decrease of i.v. iron was expected to be €167,031over the next four years (Table 5).  
At patient level, the average annual cost per patient in the current scenario decreases from 
2017 to 2020 from €1,367 to €1,324 and further, the cost per patient would be less with 
€1,275 in the alternative scenario. The average cost per patient over the period 2017-2020 
with the increase in the market share of Fisiogen Ferro Forte® was €32 lower with €1,345 
annual costs per patient than in the current scenario with €1,314 (Table 5). 
Deterministic sensitivity analysis 
One-way sensitivity analyses were conducted to examine how changes in key model 
parameters might affect the results of the base case analysis. The parameters that were varied 
included the percentage of patients with iron deficiency, the percentage of patient candidates 
for i.v. iron, the market shares for Fisiogen Ferro Forte® and the monthly cost of Fisiogen Ferro 
Forte®. The results of varying each parameter are shown in Table 6-8.  
The model was most sensitive to the percentage of patient candidates to i.v. iron for all the 
subgroups, resulting in the largest overall decrease in budget impact of €644,642, €951,806 
and €310.063 for the pre-dialysis, peritoneal dialysis and post-transplant subgroups, 
respectively.  
The model was also sensitive to the drug cost per month of Fisiogen Ferro Forte® for all the 
subgroups, resulting in overall decrease in budget impact of €478,355, €946,629 and €246,386 
for the pre-dialysis, peritoneal dialysis and post-transplant subgroups, respectively.  
 
4. DISCUSSION 
This study compares the costs of three i.v. iron products (Ferinject®, Venofer® and Feriv®) and 
an oral iron product (Fisiogen Ferro Forte®) and estimates the budget impact for the treatment 
of iron deficiency in three groups of nephrology patients: pre-dialysis, peritoneal dialysis and 
post-transplant. Results of the budget impact analysis suggest that the increasing use of 
Fisiogen Ferro Forte® would result in a four-year adjusted total budget savings for the Spanish 
NHS of €376,041, €898,928 and €206,708 for pre-dialysis, peritoneal dialysis and post-
transplant respectively at a national level.  
The main reason for these budget impact results is that the growing use of Fisiogen Ferro 
Forte®, as it is an oral iron does not involve any use of the healthcare centre or healthcare 
professional during its administration.  
In this pharmacoeconomic analysis we have only considered the Spanish NHS perspective, 
which involves the drug acquisition cost and the i.v administration cost, as well as the 
healthcare professionals,the possible laboratory tests needed and the outpatient 
hospitalizations associated with the administration of i.v. iron formulations. But we have not 
considered the society perspective, which will include patients transportation cost and 
patients working days losses. 
Carlos Rubió-Terrés et al [5], in their pharmacoeconomic analysis of the treatment of iron 
deficiency with Ferinject® in Spain have considered both perspectives. The results obtained 
from the NHS perspective shown that the use of Ferinject® would generate a saving by 
treatment of iron deficiency of 183 € compared to iron dextran and from 131 € to 164 € 
compared to iron sucrose. From the society perspective, savings would be 262 € and 143 € to 
177 €, respectively. 
One of the strengths for our analysis is that due to the lack of published clinical input data on 
drug use, medical resource utilisation and treatment of i.v. iron this study was based on the 
real-world use of these treatments as input data was based on the expert opinion of 
nephrologists working in different Spanish hospitals. However, these experts opinion may have 
caused a bias in the study since only a few experts have been involved, which do not cover all 
regions of Spain. The results obtained in our analysis can be considered conservative since if 
indirect costs were considered, such as the loss of working hours due to the stay in the day 
hospital for i.v. iron to be administered, clearly the treatment with Fisiogen Ferro Forte® would 
produce even more important savings than those already obtained without considering these 
costs. 
5. CONCLUSIONS 
The results from our analysis suggest that when the market share of Fisiogen Ferro Forte® 
increases of 3%, 5%, 8% and 10% for the next four years while the use of i.v. iron decreases, it 
would result in a €376,041, €898,928 and €206,708 decrease in the overall budget over the 
period 2017-2020 for pre-dialysis, peritoneal dialysis and post-transplant groups respectively. 
These saving would be possible due to lower expected drug costs and healthcare resource 
utilisation costs. Although the economic impact of iron deficiency treatment has shown to 
increase over the next four years due to population growth the increase in the use of Fisiogen 
Ferro Forte® for the treatment of iron deficiency shows to reduce the average annual cost per 





Figure 1. Target population of the study 




Table 1. Drugs, dosage, costs per dose, usage percentages  









% of patients using 
the dose 
Pre-dialysis Ferinject® 500 mg 500 mg 1 100.20 € 10% 
1000 mg 500 mg 2 200.40 € 80% 
1500 mg 500 mg 3 300.60 € 10% 
Venofer® 1000 mg 200 mg 5 115.68 € 100% 
Feriv® 1000 mg 200 mg 5 82.62 € 10% 
1200 mg 200 mg 6 99.15 € 60% 
1600 mg 200 mg 8 132.20 € 30% 
 Treatments per year  Drug cost per year % of patients  
Fisiogen Ferro 
Forte ® 
1 treatment of 3 months  63.69 € 5% 
2 treatments of 3 months  127.39 € 15% 
3 treatments of 3 months  191.08 € 20% 
4 treatments of 3 months  254.77 € 60% 












Ferinject® 500 mg 500 mg 1 100.20 € 40% 
1000 mg 500 mg 2 200.40 € 60% 
Venofer® 1000 mg 200 mg 5 115.68 € 100% 
Feriv® 600 mg 200 mg 3 49.57 € 20% 
800 mg 200 mg 4 66.10 € 60% 
1200 mg 200 mg 6 99.15 € 20% 
 Treatments per year  Drug cost per year % of patients  
Fisiogen Ferro 
Forte ® 
1 treatment of 3 months  60.66 € 10% 
2 treatments of 3 months  121.32 € 30% 
3 treatments of 3 months  181.98 € 5% 
4 treatments of 3 months  242.64 € 55% 








% of patients using 
the dose 
Post-transplant Ferinject® 500 mg 500 mg 1 100.20 € 30% 
1000 mg 500 mg 2 200.40 € 60% 
1500 mg 500 mg 3 300.60 € 10% 
Venofer® 1000 mg 200 mg 5 115.68 € 100% 
Feriv® 1000 mg 200 mg 5 82.62 € 100% 
 Treatments per year  Drug cost per year % of patients  
Fisiogen Ferro 
Forte ® 
3 treatments of 3 months  181.98 € 20% 




Table 2.  Drug cost, medical resource utilisation and unit costs and average cost per patient per year 
Stage of 
disease 
Annual resources Ferinject® Venofer® Feriv® 
Fisiogen Ferro 
Forte® 
Unit costs in € 
2017 
Pre-dialysis Drug cost (€) 203.36 € 130.48 € 126.65 € 213.37 € - 
Medical visits      
Specialist physician  4 12 6 5 64.19 € 
Primary Care 0 2 0 0 38.45 € 
Nurse 2 5 6.5 0 20.63 € 
Annual cost (€) 298.02 € 950.33 € 519.24 € 320.95 € - 
Day hospital Annual cost (€) 54.62 € 227.60 € 295.88 € 0.00 € - 
Laboratory tests      
Study of ferric metabolism (TSAT 
and ferritin) 
4 4 6 5 17.30 € 
Haemoglobin level monitoring 4 4 6 5 9.58 € 
Annual cost (€) 107.52 € 107.52 € 161.28 € 134.40 € - 
Total cost per patient in € 663.52 € 1,415.93 € 1,103.05 € 668.72 € - 
Peritoneal 
dialysis 
Drug cost (€) 162.69 € 130.48 € 81.83 € 185.01 € - 
Medical visits      
Specialist physician  6 12 6 6 64.19 € 
Primary Care 0 2 0 0 38.45 € 
Nurse 1.6 5 4.2 0 20.63 € 
Annual cost (€) 418.15 € 950.33 € 471.79 € 385.14 € - 
Day hospital Annual cost (€) 43.70 € 227.60 € 191.18 € 0.00 € - 
Laboratory tests      
Study of ferric metabolism (TSAT 
and ferritin) 
6 4 6 6 17.30 € 
Haemoglobin level monitoring 6 12 6 6 9.58 € 
Annual cost (€) 161.28 € 184.16 € 161.28 € 161.28 € - 
Total cost per patient in € 785.82 € 1,492.57 € 906.08 € 731.43 € - 
Post-
transplant 
Drug cost (€) 183.03 € 130.48 € 97.42 € 230.51 € - 
 Medical visits      
 Specialist physician  4 12 12 4 64.19 € 
 Primary Care 0 2 2 0 38.45 € 
 Nurse 1.8 5 5 0 20.63 € 
 Annual cost (€) 293.89 € 950.33 € 950.33 € 256.76 € - 
 Day hospital Annual cost (€) 49.16 € 227.60 € 227.60 € 0.00 € - 
 Laboratory tests      
 Study of ferric metabolism (TSAT 
and ferritin) 
4 4 4 4 17.30 € 
 Haemoglobin level monitoring 4 12 12 4 9.58 € 
 Annual cost (€) 107.52 € 184.16 € 184.16 € 107.52 € - 
 Total cost per patient in € 663.60 € 1,492.57 € 1,459.51 € 594.79 € - 
 
Table 3. Market shares (%): Base case analysis and alternative scenario 
Base case analysis 2017 2018 2019 2020 
Ferinject® 12.74% 14.30% 15.85% 17.41% 
Venofer® 38.02% 33.57% 29.12% 24.66% 
Feriv® 49.24% 52.13% 55.03% 57.93% 
Fisiogen Ferro Forte® 0.00% 0.00% 0.00% 0.00% 
Alternative scenario 2017 2018 2019 2020 
Ferinject® 11.74% 12.63% 13.18% 14.08% 
Venofer® 37.02% 31.90% 26.45% 21.33% 
Feriv® 48.24% 50.46% 52.36% 54.60% 
Fisiogen Ferro Forte® 3.00% 5.00% 8.00% 10.00% 
 
  Table 4. Target population for intravenous iron treatment 
Stage of 
disease Target population 2017 2018 2019 2020 
Pre-dialysis Adult patients with CKD in pre-dialysis stage 10,843 10,825 10,807 10,792 
Adult patients with CKD in pre-dialysis stage who have iron 
deficiency 
7,048 7,036 7,025 7,015 
Adult patients with CKD in pre-dialysis stage who have iron 
deficiency candidates for intravenous iron 
3,700 3,694 3,688 3,683 
Peritoneal 
dialysis 
Adult patients with CKD stage 5D  51,575 51,501 51,421 51,334 
Adult patients with stage 5D CKD in peritoneal dialysis 2,837 2,833 2,828 2,823 
Adult patients with stage 5D CKD in peritoneal dialysis who have 
iron deficiency 
2,340 2,337 2,333 2,329 
Adult patients with stage 5D CKD in peritoneal dialysis who have 
iron deficiency candidates for intravenous iron 
1,989 1,986 1,983 1,980 
Post-
transplant 
Adult patients with CKD stage 5D  51,575 51,501 51,421 51,334 
Adult patients with stage 5D CKD with a functional transplant 26,561 26,523 26,482 26,437 
Adult patients with stage 5D CKD with a functional transplant who 
have iron deficiency 
13,281 13,262 13,241 13,219 
Adult patients with stage 5D CKD with a functional transplant who 
have iron deficiency candidates for intravenous iron 
1,328 1,326 1,324 1,322 
 
Table 5. Results of the base case budget impact analysis 
Pre-dialysis Current scenario 2017 2018 2019 2020 Total 
Ferinject® 312,791 € 350.492 € 387.858 € 425.438 € 1.476.579 € 
Venofer® 1,991,955 € 1.755.808 € 1.520.611 € 1.285.919 € 6.554.293 € 
Feriv® 2,009,730 € 2.124.054 € 2.238.610 € 2.353.294 € 8.725.688 € 
Fisiogen Ferro Forte® 0 € 0 € 0 € 0 € 0 € 
Total cost (€) 4,314,475 € 4.230.354 € 4.147.079 € 4.064.652 € 16.756.560 € 
Alternative scenario 2017 2018 2019 2020 Total 
Ferinject® 288,239 € 309.642 € 322.603 € 343.983 € 1.264.468 € 
Venofer® 1,939,563 € 1.668.636 € 1.381.361 € 1.112.099 € 6.101.659 € 
Feriv® 1,968,915 € 2.056.145 € 2.130.131 € 2.217.884 € 8.373.074 € 
Fisiogen Ferro Forte® 74,232 € 123.509 € 197.297 € 246.278 € 641.317 € 
Total cost (€) 4,270,949 € 4.157.933 € 4.031.392 € 3.920.245 € 16.380.519 € 
Budget impact savings -43,527 € -72.421 € -115.687 € -144.407 € -376.041 € 
Peritoneal 
dialysis 
Current scenario 2017 2018 2019 2020 Total 
Ferinject® 199,142 € 223.208 € 247.016 € 999.610 € 1.668.977 € 
Venofer® 1,128,805 € 995.263 € 861.986 € 728.738 € 3.714.792 € 
Feriv® 887,483 € 938.230 € 988.879 € 1.039.242 € 3.853.835 € 
Fisiogen Ferro Forte® 0 € 0 € 0 € 0 € 0 € 
Total cost (€) 2,215,431 € 2.156.702 € 2.097.881 € 2.767.590 € 9.237.604 € 
Alternative scenario 2017 2018 2019 2020 Total 
Ferinject® 183,511 € 197.193 € 205.457 € 219.011 € 805.172 € 
Venofer® 1,099,116 € 945.851 € 783.049 € 630.233 € 3.458.249 € 
Feriv® 869,460 € 908.234 € 940.960 € 979.444 € 3.698.097 € 
Fisiogen Ferro Forte® 43,648 € 72.644 € 116.049 € 144.817 € 377.158 € 
Total cost (€) 2,195,735 € 2.123.922 € 2.045.515 € 1.973.504 € 8.338.676 € 
Budget impact savings -19,696 € -32.780 € -52.366 € -794.086 € -898.928 € 
Post-transplant Current scenario 2017 2018 2019 2020 Total 
Ferinject® 107,201 € 120.156 € 132.972 € 145.815 € 506.145 € 
Venofer® 753,634 € 664.476 € 575.495 € 486.534 € 2.480.140 € 
Feriv® 954,423 € 1.008.998 € 1.063.467 € 1.117.628 € 4.144.516 € 
Fisiogen Ferro Forte® 0 € 0 € 0 € 0 € 0 € 
Total cost (€) 1,815,259 € 1.793.630 € 1.771.935 € 1.749.977 € 7.130.800 € 
Alternative scenario 2017 2018 2019 2020 Total 
Ferinject® 98,787 € 106.152 € 110.601 € 117.897 € 433.436 € 
Venofer® 733,812 € 631.487 € 522.794 € 420.768 € 2.308.862 € 
Feriv® 935,040 € 976.739 € 1.011.933 € 1.053.319 € 3.977.031 € 
Fisiogen Ferro Forte® 23,697 € 39.439 € 63.004 € 78.623 € 204.763 € 
Total cost (€) 1,791,336 € 1.753.817 € 1.708.332 € 1.670.607 € 6.924.092 € 





Table 6. One-way sensitivity analysis for the pre-dialysis subgroup  
One-way sensitivity analysis Budget impact analysis 
Model parameter Value in model Sensitivity analysis 2017 2018 2019 2020 Total 
Base case   -43,527 € -72.421 € -115.687 € -144.407 € -376.041 € 
Adult patients with CKD in pre-
dialysis stage who have iron 
deficiency 
65% 
50% -33.482 € -55.708 € -88.990 € -111.082 € -289.263 € 
80% -53.571 € -89.133 € -142.384 € -177.732 € -462.820 € 
Adult patients with CKD in pre-
dialysis stage who have iron 




-12.436 € -20.692 € -33.053 € -41.259 € -107.440 € 
90% 
-74.617 € -124.150 € -198.320 € -247.555 € -644.642 € 
Market share projection 
(Fisiogen Ferro Forte® increase) 
3% - 5% - 8% - 10% 
2% - 4% - 6% - 8% -29.018 € -57.937 € -86.765 € -115.526 € -289.245 € 
3% - 6% - 9% - 12% -43.527 € -86.905 € -130.148 € -173.288 € -433.868 € 
Fisiogen Ferro Forte® monthly 
cost 
20.22 € 
10.11 € -55.370 € -92.125 € -147.163 € -183.697 € -478.355 € 
30.33 € -31.684 € -52.716 € -84.211 € -105.117 € -273.728 € 
 
Table 7. One-way sensitivity analysis for the peritoneal dialysis subgroup  
One-way sensitivity analysis Budget impact analysis 
Model parameter Value in model Sensitivity analysis 2017 2018 2019 2020 Total 
Base case   -19,696 € -32.780 € -52.366 € -794.086 € -898.928 € 
Adult patients with stage 5D 
CKD in peritoneal dialysis who 
have iron deficiency 
82,5% 
80% -19.099 € -31.787 € -50.780 € -770.022 € -871.688 € 
85% -20.293 € -33.773 € -53.953 € -818.149 € -926.169 € 
Adult patients with stage 5D 
CKD in peritoneal dialysis who 
have iron deficiency candidates 
for intravenous iron 
85% 
80% 
-18.538 € -30.852 € -49.286 € -747.375 € -846.050 € 
90% 
-20.855 € -34.708 € -55.447 € -840.796 € -951.806 € 
Market share projection 
(Fisiogen Ferro Forte® increase) 
3% - 5% - 8% - 10% 
2% - 4% - 6% - 8% -13.131 € -26.224 € -39.275 € -781.016 € -859.646 € 
3% - 6% - 9% - 12% -19.696 € -39.336 € -58.912 € -807.155 € -925.100 € 
Fisiogen Ferro Forte® monthly 
cost 
20.22 € 
10.11 € -25.217 € -41.968 € -67.043 € -812.401 € -946.629 € 
30.33 € -14.176 € -23.593 € -37.689 € -775.770 € -851.228 € 
 
Table 8. One-way sensitivity analysis for the post-transplant subgroup  
One-way sensitivity analysis Budget impact analysis 
Model parameter Value in model Sensitivity analysis 2017 2018 2019 2020 Total 
Base case   -23,922 € -39.814 € -63.603 € -79.370 € -206.708 € 
Adult patients with stage 5D 
CKD with a functional 




-19.138 € -31.851 € -50.882 € -63.496 € -165.367 € 
60% 
-28.707 € -47.777 € -76.323 € -95.244 € -248.050 € 
Adult patients with stage 5D 
CKD with a functional 
transplant who have iron 




-11.961 € -19.907 € -31.801 € -39.685 € -103.354 € 
15% 
-35.884 € -59.721 € -95.404 € -119.055 
€ 
-310.063 € 
Market share projection 
(Fisiogen Ferro Forte® 
increase) 
3% - 5% - 8% - 10% 
2% - 4% - 6% - 8% -15.948 € -31.851 € -47.702 € -63.496 € -158.997 € 
3% - 6% - 9% - 12% 
-23.922 € -47.777 € -71.553 € -95.244 € -238.496 € 
Fisiogen Ferro Forte® monthly 
cost 
20.22 € 
10.11 € -28.514 € -47.456 € -75.811 € -94.605 € -246.386 € 
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